Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
10 min read
Susac syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Susac syndrome indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Foix-Alajouanine syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Foix-Alajouanine syndrome strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
Hirayama disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Hirayama disease indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Brown-Sequard syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Brown-Sequard syndrome strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
Charcot-Marie-Tooth disease type 4J Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Charcot-Marie-Tooth disease type 4J strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Latest Hotspot
10 min read
Charcot-Marie-Tooth disease type 2E Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Charcot-Marie-Tooth disease type 2E strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Latest Hotspot
10 min read
Kennedy disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Kennedy disease indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Hereditary sensory and autonomic neuropathy type 4 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Hereditary sensory and autonomic neuropathy type 4 strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built.
Latest Hotspot
10 min read
Hereditary sensory and autonomic neuropathy type 3 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Hereditary sensory and autonomic neuropathy type 3 strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built.
Latest Hotspot
10 min read
Hereditary sensory and autonomic neuropathy type 1 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Hereditary sensory and autonomic neuropathy type 1 strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built.
Latest Hotspot
10 min read
Spastic paraplegia type 2 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Spastic paraplegia type 2 strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
Hereditary spastic paraplegia type 5A Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Hereditary spastic paraplegia type 5A strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap.